News Archive

The below is a republication of a story that featured DCRI’s Kanecia Zimmerman, MD, MPH, which appeared in Duke University School of Medicine’s digital publication, Magnify.

Over a third of patients with diabetes and heart disease were not taking any of the three therapies proven to prevent major adverse cardiovascular events.

A recent letter to the editor provided recommendations for encouraging open science in COVID-19 clinical trials, such as incentives for data sharing during the project funding stage.

The rate of transmission within schools was found to be much lower than the rate of community spread of the disease.

Perakslis will provide strategic vision and oversight of DCRI’s digital research initiatives and technology affairs to advance the academic institute’s clinical research portfolio.

The Duke Clinical Research Institute (DCRI) and Verily are utilizing the HERO Registry and community to launch a study to gain long-term insights about the COVID-19 vaccine developed by Pfizer and BioNTech, including real-world safety data. This study, which is funded by Pfizer, will follow vaccinated healthcare workers for two years to assess their experiences after receiving the vaccine.

DCRI researchers have created a blueprint to automatically update clinicians on their prescribing habits and those of their peers.

DCRI population health scientists conducted a discrete choice experiment to improve understanding of how people weigh risks associated with COVID-19.

The annual list, which examined papers published over the last decade, honors researchers who were in the top 1 percent of citations in their fields.

Two presentations on the American Heart Association COVID Registry shared data about COVID-19 hospitalizations collected from over 100 hospitals.